The present disclosure relates to a nucleic acid detection method, a compound, and a fluorescent probe. This application claims priority on Japanese Patent Application No. 2020-206368 filed on Dec. 11, 2020, the entire content of which is incorporated herein by reference.
PATENT LITERATURE 1 discloses a compound as a DNA probe. A representative compound disclosed in PATENT LITERATURE 1 is quinone cyanine-dithiazole (QCy-DT).
QCy-DT is a “donor-two-acceptor (D2A)” π-electronic system in which two acceptors are bound to one donor. QCy-DT is one class belonging to D2A fluorophore (Qcy7).
QCy-DT includes a donor phenol moiety and two heterocyclic electron acceptors bound to the donor phenol moiety.
QCy-DT has a molecular structure in a curved shape and can bind to a minor groove of a double-stranded DNA. Upon binding to a double-stranded DNA, QCy-DT is converted into a switch-on near-infrared fluorophore through internal charge transfer. That is, upon binding to a double-stranded DNA, QCy-DT emits fluorescence. QCy-DT is used as a fluorescent probe for detection of double-stranded DNAs.
Similar to PATENT LITERATURE 1, NON PATENT LITERATURE 1 discloses QCy-DT. NON PATENT LITERATURE 2 discloses a “donor-two-acceptor (D2A)” dye. NON PATENT LITERATURE 2 discloses various examples of potential acceptor moieties.
QCy-DT cannot detect a quadruplex nucleic acid. In addition, none of the afore-mentioned literatures discloses detection of a quadruplex nucleic acid nor detection of a double-stranded nucleic acid and a quadruplex nucleic acid so as to be distinguished from each other. Further, none of the literatures discloses measurement of viscosity by a fluorescent probe. It is desired to solve at least one of these problems.
An aspect of the present disclosure is a method including using a compound for nucleic acid detection. The compound used in the method of the disclosure has a structure represented by general formula (1A) or general formula (1B) according to an embodiment described later.
Another aspect of the present disclosure is a compound. The compound of the disclosure has a structure represented by general formula (1A) or general formula (1B) according to the embodiment described later.
Another aspect of the present disclosure is a fluorescent probe. The fluorescent probe of the disclosure includes the compound described above.
Another aspect of the present disclosure is a method including using the compound described above for measurement of a viscosity of a liquid.
The compound of the present disclosure may be a compound including: a donor; and three acceptors bound to the donor so as to perform rotary motion with respect to the donor, wherein fluorescence from the compound changes in accordance with change in the rotary motion of each acceptor. A method of the present disclosure may be a method including using a compound including: a donor; and three acceptors bound to the donor so as to perform rotary motion with respect to the donor, wherein fluorescence from the compound changes in accordance with change in the rotary motion of each acceptor. The using of the compound may be for nucleic acid detection or for measurement of a viscosity of a liquid.
Further details will be described later as an embodiment.
RA, RB, and RC each independently have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F) below (* representing a binding site).
Before describing D3A shown in
The Qcy7 (quinone cyanine) fluorescent dye is one class of a cyanine fluorescent probe (cyanine fluorescent dye). Typically, in Qcy7, two heterocyclic electron acceptors are bound to the donor phenol moiety, and the heterocyclic electron acceptors in Qcy7 are, for example, alkylated quinolines, indolines, or pyridines.
QCy-DT is activated through deprotonation, and functions as a near-infrared fluorescent probe. The donor phenol moiety 111 becomes a phenolate through deprotonation. The phenolate provides an electron to either one (N-alkylated benzothiazole) of the two acceptors 112A, 112B, to trigger internal charge transfer to a nitrogen atom included in the other acceptor of the two acceptors 112A, 112B.
QCy-DT includes benzothiazolium cations (benzothiazole groups) as the acceptors 112A, 112B. Each of the two acceptors 112A, 112B included in QCy-DT can perform rotary motion (twist) about the binding to the donor 111, with the binding serving as a rotation axis. When the rotation of the acceptors 112A, 112B is suppressed or stopped, the fluorescence property of QCy-DT changes. That is, in QCy-DT, the fluorescence property changes in accordance with change in the rotary motion of the acceptors 112A, 112B. The fluorescence property that changes is at least either one of fluorescence wavelength or fluorescence intensity, for example.
When the acceptors 112A, 112B are rotating, the fluorescence is quenched or the intensity thereof decreases. Meanwhile, when the rotation of the acceptors 112A, 112B is suppressed or stopped, the fluorescence intensity at a specific wavelength increases. That is, QCy-DT does not emit fluorescence when the acceptors 112A, 112B are rotating, and emits fluorescence when the rotation of the acceptors 112A, 112B is stopped.
QCy-DT can bind to a minor groove of a double-stranded DNA. When the acceptor 112A, 112B of QCy-DT is not bound to a double-stranded DNA, suppression of the rotation is small, and fluorescence is quenched. However, as shown in
When rotation of both acceptors 112A, 112B is suppressed or stopped due to binding of QCy-DT to a double-stranded DNA, charge transfer is caused between the acceptors 112A, 112B (in this case, one acceptor out of both acceptors 112A, 112B serves as a donor of a charge, and the other acceptor serves as an acceptor of the charge). Since charge transfer occurs between the acceptors 112A, 112B whose rotation is stopped or suppressed, QCy-DT can emit fluorescence having a long wavelength.
As described above, QCy-DT has a D2A structure, and when the two acceptors 112A, 112B bind to a minor groove of a double-stranded nucleic acid, rotation of the acceptor 112A, 112B is suppressed or stopped, and QCy-DT can emit fluorescence. That is, QCy-DT emits fluorescence upon binding to a minor groove of a double-stranded nucleic acid, whereas, when QCy-DT is not bound thereto, fluorescence becomes weaker than that when QCy-DT is bound thereto. Further, in QCy-DT, since charge transfer is caused between the two acceptors 112A, 112B whose rotation has been suppressed or stopped, QCy-DT can emit fluorescence having a long wavelength.
Further, QCy-DT has sequence selectivity. That is, QCy-DT binds to an AT-rich sequence in a nucleic acid. More specifically, QCy-DT specifically binds to a double-stranded nucleic acid having a sequence of 5′-AAATTT-3′. The bond is a hydrogen bound, for example.
With reference back to
The donor phenol moiety 11 having been deprotonated becomes a phenolate. The phenolate provides an electron to any one of the three acceptors 12A, 12B, 12C.
Each of the acceptors 12A, 12B, 12C included in the compound 10 according to the embodiment can perform rotary motion (twist) about the binding to the donor 11, with the binding serving as a rotation axis, similar to the acceptors 112A, 112B included in QCy-DT. The bond with each acceptor 12A, 12B, 12C is a dimethine bond, for example.
Similar to QCy-DT, the compound 10 may be capable of binding to a minor groove of a double-stranded nucleic acid (double-stranded DNA: dsDNA). When two acceptors arbitrarily selected from among the three acceptors 12A, 12B, 12C are focused on, the compound 10 can have a structure similar to that of QCy-DT being D2A. For example, in the compound 10 being D3A, when the donor 11, the first acceptor 12A, and the second acceptor 12B are focused on, the compound 10 can have a structure similar to that of QCy-DT being D2A. Further, also when the donor 11, the second acceptor 12B, and the third acceptor 12C are focused on, the compound 10 can have a structure similar to that of QCy-DT being D2A. Further, also when the donor 11, the third acceptor 12C, and the first acceptor 12A are focused on, the compound 10 can have a structure similar to that of QCy-DT being D2A.
Therefore, similar to QCy-DT, the compound 10 may be capable of binding to a minor groove of a double-stranded nucleic acid such as a double-stranded DNA, by means of two acceptors arbitrarily selected from among the three acceptors 12A, 12B, 12C.
For example, a pair of the first acceptor 12A and the second acceptor 12B in the compound 10 can bind to a minor groove of a double-stranded DNA. In this case, rotation of the first acceptor 12A and the second acceptor 12B bound to the minor groove is suppressed or stopped. When the rotation of the two acceptors 12A, 12B is suppressed or stopped, fluorescence (near-infrared radiation) having a specific wavelength is caused, similar to QCy-DT. However, the third acceptor 12C not bound to the minor groove is rotatable.
A pair of the second acceptor 12B and the third acceptor 12C in the compound 10 can bind to a minor groove of a double-stranded DNA. In this case, rotation of the second acceptor 12B and the third acceptor 12C bound to the minor groove is suppressed or stopped. When the rotation of the two acceptors 12B, 12C is suppressed or stopped, fluorescence (near-infrared radiation) having a specific wavelength is caused, similar to QCy-DT. However, the first acceptor 12A not bound to the minor groove is rotatable.
A pair of the third acceptor 12C and the first acceptor 12A in the compound 10 can bind to a minor groove of a double-stranded DNA. In this case, rotation of the third acceptor 12C and the first acceptor 12A bound to the minor groove is suppressed or stopped. When the rotation of the two acceptors 12C, 12A is suppressed or stopped, fluorescence (near-infrared radiation) having a specific wavelength is caused, similar to QCy-DT. However, the second acceptor 12B not bound to the minor groove is rotatable.
As described above, in the compound 10 which is of a three-leg type, the fluorescence property changes in accordance with change in rotary motion of the acceptors 12A, 12B, 12C, similar to QCy-DT. Therefore, preferably, the compound 10 can be used as a fluorescent probe (fluorescent dye) for detection of a double-stranded nucleic acid. That is, the compound 10 may emit fluorescence upon binding to a minor groove of a double-stranded nucleic acid, whereas, when the compound 10 is not bound thereto, the fluorescence intensity may become lower than that when the compound 10 is bound thereto. It should be noted that, in the compound 10 as well, charge transfer is caused between acceptors whose rotation has been stopped or suppressed, and thus, the compound 10 can emit fluorescence having a long wavelength. Further, the compound 10 may have sequence selectivity, similar to QCy-DT. That is, the compound 10 may bind to an AT-rich sequence in a nucleic acid. More specifically, the compound 10 may specifically bind to a double-stranded nucleic acid having a sequence of 5′-AAATTT-3′.
The compound 10, which is of a three-leg type, can bind not only to a double-stranded nucleic acid but also a quadruplex nucleic acid. Since the compound 10 of the three-leg type includes three acceptors 12A, 12B, 12C, the compound 10 has a molecular structure in a planar shape as a whole, when compared with the compound 100 of the two-leg type. Being in a planar shape, the compound 10 can bind to a G4 plane (G-Quartet) of a quadruplex nucleic acid.
Here, the quadruplex nucleic acid is also referred to as a guanine quadruplex (G-quadruplex: G4). The G-quadruplex is formed by a DNA or RNA that is rich in guanine. The G-quadruplex has a structure in which plane structures (G4 planes) each referred to as a G-Quartet formed by four guanine bases are stacked. The structure of the G-quadruplex (G4) may be any of a parallel type, an antiparallel type, and a hybrid type. With any structure thereamong, the G-quadruplex has a G4 plane formed by four guanine bases.
Being in a planar shape, the compound 10 has a characteristic of easily binding to the G4 plane (G-Quartet), which is also a plane. That is, the compound 10 in a planar shape can bind to the G4 plane so as to overlap the G4 plane in a planar manner. The bond between the compound 10 and the quadruplex nucleic acid may be a hydrophobic bond, or may be realized as a stack due to a binding force generated between planes through n-x stacking interaction.
Since the compound 10 overlaps the G4 plane in a planar manner, all of the three acceptors 12A, 12B, 12C bind to the quadruplex nucleic acid. Therefore, when the compound binds to the quadruplex nucleic acid, rotation of all of the three acceptors 12A, 12B, 12C is suppressed or stopped. When the rotation of the three acceptors 12A, 12B, 12C is suppressed or stopped, fluorescence (near-infrared radiation) is caused. Thus, the compound 10 of the three-leg type can be used as a fluorescent probe (fluorescent dye) for detection of a quadruplex nucleic acid. That is, the compound 10 emits fluorescence upon binding to a quadruplex nucleic acid, whereas, when the compound 10 is not bound thereto, the fluorescence intensity becomes lower than that when the compound 10 is bound thereto.
When rotation of all of the three acceptors 12A, 12B, 12C is suppressed or stopped, fluorescence (near-infrared radiation) having a wavelength different from that when rotation of two acceptors is suppressed or stopped, is caused. That is, the wavelength at which the fluorescence intensity increases when the compound 10 binds to a double-stranded nucleic acid, and the wavelength at which the fluorescence intensity increases when the compound 10 binds to a quadruplex nucleic acid are different from each other. Therefore, when the compound 10 is used to detect a nucleic acid, whether the detected nucleic acid is a double-stranded nucleic acid or a quadruplex nucleic acid can be distinguished by the color of the fluorescence (the wavelength of the fluorescence), from the compound 10, whose fluorescence intensity increases.
As described above, the compound 10 emits fluorescence when rotation of a part or all of the three acceptors 12A, 12B, 12C is suppressed or stopped. Fluorescence occurs not only when binding to a double-stranded nucleic acid or a quadruplex nucleic acid, but also when rotation of a part or all of the three acceptors 12A, 12B, 12C is suppressed or stopped due to another factor. The other factor is the viscosity of a liquid in which the compound 10 is present, for example. When the viscosity is high, rotation of the acceptors 12A, 12B, 12C is suppressed.
The compound 10 is represented by general formula (1A) or general formula (1B) described above, for example. The compound 10 is of a three-leg type and is used as a novel quinone cyanine fluorescent probe (quinone cyanine fluorescent dye).
The compound 10 represented by general formula (1A) has phenol as the donor 11 (donor moiety), and three acceptors (acceptor moieties: RA, RB, and RC in general formula (1A), (1B)) are bound to the phenol. The compound 10 represented by general formula (1B) is one (activated compound 10) obtained by deprotonating the compound 10 represented by general formula (1A), and the phenol in general formula (1A) has been changed to a phenolate. The activated compound 10 functions as a near-infrared fluorescent probe.
RA, RB, and RC (acceptors) in general formula (1A), (1B) each independently have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F) described above. With respect to RA, RB, and RC, all of them may have a structure represented by formula (1C), all of them may have a structure represented by formula (1D), all of them may have a structure represented by formula (1E), or all of them may have a structure represented by formula (1F). All of RA, RB, and RC in general formula (1A), (1B) may have structures different from each other. The structure represented by formula (1D) is more planar than the structure represented by formula (1C), and is advantageous for binding to a quadruplex nucleic acid. The structure represented by formula (1E) is more planar than the structure represented by formula (1C), and is advantageous for binding to a quadruplex nucleic acid. The structure represented by formula (1F) is more planar than the structure represented by formula (1D), and is advantageous for binding to a quadruplex nucleic acid.
RA may have the structure represented by formula (1C), RB may have the structure represented by formula (1C), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1C), RB may have the structure represented by formula (1D), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1C), RB may have the structure represented by formula (1E), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1C), RB may have the structure represented by formula (1F), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1D), RB may have the structure represented by formula (1C), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1D), RB may have the structure represented by formula (1D), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1D), RB may have the structure represented by formula (1E), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1D), RB may have the structure represented by formula (1F), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1E), RB may have the structure represented by formula (1C), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1E), RB may have the structure represented by formula (1D), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1E), RB may have the structure represented by formula (1E), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1E), RB may have the structure represented by formula (1F), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1F), RB may have the structure represented by formula (1C), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1F), RB may have the structure represented by formula (1D), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1F), RB may have the structure represented by formula (1E), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
RA may have the structure represented by formula (1F), RB may have the structure represented by formula (1F), and RC may have a structure selected from the group consisting of formula (1C), formula (1D), formula (1E), and formula (1F).
Examples of general acceptors are described in PATENT LITERATURE 1, which discloses QCy-DT. Therefore, as the acceptors included in the compound 10, acceptors similar to those described in PATENT LITERATURE 1 can be adopted. In selection of the acceptors, NON PATENT LITERATURE 1 and NON PATENT LITERATURE 2 may be referred to. In formula (1C), (1D), (1E), or (1F), X is preferably selected from the group consisting of O, S, and Se, similar to PATENT LITERATURE 1. When X is an element selected from the group consisting of O, S, and Se, each acceptor can perform rotary motion. More preferably, X is S.
Similar to PATENT LITERATURE 1, R1 in formula (1D), (1D), (1E), or (1E) is preferably H or —(CH2)n-. R1 may be —(CH2CH2O)n-. That is, R1 is preferably selected from the group consisting of H, —(CH2)n-, and —(CH2CH2O)n-. Here, n is a natural number of 1 to 100. When n is changed, the rotation speed of the acceptor can be controlled.
Preferably, R3 is H or —(CH2)n-. R3 may be —(CH2CH2O)n-. That is, R3 is preferably selected from the group consisting of H, —(CH2)n-, and —(CH2CH2O)n-. Here, n is a natural number of 1 to 100. When n is changed, the rotation speed of the acceptor can be controlled.
Preferably, R5 is H or —(CH2)n-. R5 may be —(CH2CH2O)n-. That is, R5 is preferably selected from the group consisting of H, —(CH2)n-, and —(CH2CH2O)n-. Here, n is a natural number of 1 to 100. When n is changed, the rotation speed of the acceptor can be controlled.
Preferably, R7 is H or —(CH2)n-. R5 may be —(CH2CH2O)n-. That is, R5 is preferably selected from the group consisting of H, —(CH2)n-, and —(CH2CH2O)n-. Here, n is a natural number of 1 to 100. When n is changed, the rotation speed of the acceptor can be controlled.
—R1-R2 may be —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3), and in this case, the compound 10 is suitable as a viscosity probe for viscosity measurement. When —R1-R2 is —(CH2)n-H, n is preferably a natural number of 1 to 18. When —R1-R2 is —(CH2CH2O)n-H or —(CH2CH2O)n-CH3, n is preferably a natural number of 1 to 100, more preferably a natural number of 1 to 36, and further preferably a natural number of 1 to 6.
—R3-R4 may be —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3), and in this case, the compound 10 is suitable as a viscosity probe for viscosity measurement. When —R3-R4 is —(CH2)n-H, n is preferably a natural number of 1 to 18. When —R3-R4 is —(CH2CH2O)n-H or —(CH2CH2O)n-CH3, n is preferably a natural number of 1 to 100, more preferably a natural number of 1 to 36, and further preferably a natural number of 1 to 6.
—R5-R6 may be —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3), and in this case, the compound 10 is suitable as a viscosity probe for viscosity measurement. When —R5-R6 is —(CH2)n-H, n is preferably a natural number of 1 to 18. When —R5-R6 is —(CH2CH2O)n-H or —(CH2CH2O)n-CH3, n is preferably a natural number of 1 to 100, more preferably a natural number of 1 to 36, and further preferably a natural number of 1 to 6.
—R7-R8 may be —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3), and in this case, the compound 10 is suitable as a viscosity probe for viscosity measurement. When —R7-R8 is —(CH2)n-H, n is preferably a natural number of 1 to 18. When —R7-R8 is —(CH2CH2O)n-H or —(CH2CH2O)n-CH3, n is preferably a natural number of 1 to 100, more preferably a natural number of 1 to 36, and further preferably a natural number of 1 to 6.
Similar to PATENT LITERATURE 1, R2 is also preferably selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, and sulfonate (SO3−). R2 may be an aryl group such as phenyl (C6H5), naphthyl, or pyrene, or a derivative thereof. R2 may be a heterocyclic compound such as thiophene, pyridyl, furan, imidazole, triazole, carbazole, or coumarin, or a derivative thereof. That is, R2 is preferably selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof.
R4 may also be an aryl group such as phenyl (C6H5), naphthyl, or pyrene, or a derivative thereof. R4 may be a heterocyclic compound such as thiophene, pyridyl, furan, imidazole, triazole, carbazole, or coumarin, or a derivative thereof. That is, R4 is preferably selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof.
R6 may also be an aryl group such as phenyl (C6H5), naphthyl, or pyrene, or a derivative thereof. R6 may be a heterocyclic compound such as thiophene, pyridyl, furan, imidazole, triazole, carbazole, or coumarin, or a derivative thereof. That is, R6 is preferably selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof.
R8 may also be an aryl group such as phenyl (C6H5), naphthyl, or pyrene, or a derivative thereof. R4 may be a heterocyclic compound such as thiophene, pyridyl, furan, imidazole, triazole, carbazole, or coumarin, or a derivative thereof. That is, R4 is preferably selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof.
Preferably, the compound 10 represented by general formula (1A) is a compound represented by general formula (2A) below. The compound 10 represented by general formula (2A) has adopted the structure represented by formula (1C) as all of RA, RB, and RC in general formula (1A).
Preferably, the compound 10 represented by general formula (1B) is a compound represented by general formula (2B) below. The compound 10 represented by general formula (2B) has adopted the structure represented by formula (1C) as all of RA, RB, and RC in general formula (1B).
The compound 10 represented by each of general formulae (2A) and (2B) includes a donor and three acceptors bound to the donor so as to perform rotary motion with respect to the donor, and the fluorescence property of the compound 10 changes in accordance with change in the rotary motion of each acceptor.
In general formulae (2A) and (2B), it is preferable that XA, XB, and XC are each independently selected from the group consisting of O, S, and Se. Preferably, XA, XB, and XC are each independently S. XA, XB, and XC may all be S.
Preferably, R1A, R1B, and R1C are each independently similar to R1 described above. That is, preferably, R1A, R1B, and R1C are each independently selected from the group consisting of H, —(CH2)n-, and —(CH2CH2O)n-. Here, n is a natural number of 1 to 100. R1A, R1B, and R1C may all be the same.
Preferably, R2A, R2B, and R2C are each independently similar to R2 described above. That is, preferably, R2A, R2B, and R2C are each independently selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof. R2A, R2B, and R2C may all be the same. —R1A-R2A, —R1B-R2B, and —R1C-R2C may each be independently —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3).
The compound 10 represented by each of general formulae (2A) and (2B) is suitable for detection of at least either one of a double-stranded nucleic acid and a quadruplex nucleic acid. In order to ensure binding performance to a double-stranded nucleic acid, the acceptor moieties 12A, 12B, 12C of the compound 10 preferably have structures similar to those of the acceptor moieties of QCy-DT. Meanwhile, planarity of the structure contributes to binding to a quadruplex nucleic acid. Therefore, the structures of the acceptor moieties 12A, 12B, 12C of the compound 10 may have low similarities to those of the acceptor moieties of QCy-DT. For example, when a large functional group is introduced to R2 of all of the three acceptor moieties, the binding performance to a quadruplex nucleic acid is improved due to increase in the stacking interaction through expansion of the planar structure, although the binding performance to a double-stranded nucleic acid may be decreased. In this case, the compound 10 is suitable as a quadruplex nucleic acid-selective fluorescent probe.
When, out of R2A, R2B, and R2C included in the three acceptors of the compound 10, any two are set to H, and the remaining one is set to a functional group having a high planarity, the QCy-DT structure is maintained by the two acceptors and the donor included in the compound 10. In this case, a double-stranded nucleic acid and a quadruplex nucleic acid can be detected by fluorescences having different wavelengths.
Preferably, the compound 10 represented by general formula (2A) is a compound represented by general formula (2C) below. The compound 10 represented by general formula (2C) includes three benzothiazolium cations via dimethine bonds with phenol as the center. In the compound 10 represented by general formula (2C), R1A, R1B, and R1C in general formula (2A) are CH2, and R2A, R2B, and R2C therein are H.
Preferably, the compound 10 represented by general formula (2B) is a compound represented by general formula (2D) below. In the compound 10 represented by general formula (2D), R1 in general formula (2B) is CH2, and R2 therein is H.
In general formulae (2C) and (2D), it is preferable that XA, XB, and XC are each independently selected from the group consisting of O, S, and Se. Preferably, XA, XB, and XC are each independently S. XA, XB, and XC may all be S.
As shown in
Preferably, the compound 10 represented by general formula (1A) is a compound represented by general formula (3A) below. The compound 10 represented by general formula (3A) has adopted the structure represented by formula (1D) as all of RA, RB, and RC in general formula (1A). The compound 10 represented by general formula (3A) is more planar than the compound 10 represented by general formula (2A), and is advantageous for binding to a quadruplex nucleic acid.
Preferably, the compound 10 represented by general formula (1B) is a compound represented by general formula (3B) below. The compound 10 represented by general formula (3B) has adopted the structure represented by formula (1D) as all of RA, RB, and Re in general formula (1B). The compound 10 represented by general formula (3B) is more planar than the compound 10 represented by general formula (2B), and is advantageous for binding to a quadruplex nucleic acid.
Similar to the compound 10 represented by each of general formulae (2A) and (2B), the compound 10 represented by each of general formulae (3A) and (3B) includes a donor and three acceptors bound to the donor so as to perform rotary motion with respect to the donor, and the fluorescence property of the compound 10 changes in accordance with change in the rotary motion of each acceptor.
In general formulae (3A) and (3B), it is preferable that XA, XB, and XC are each independently selected from the group consisting of O, S, and Se. Preferably, XA, XB, and XC are each independently S. XA, XB, and XC may all be S.
Preferably, R3A, R3B, and R3C are each independently similar to R1 or R3 described above. That is, preferably, R3A, R3B, and R3C are each independently selected from the group consisting of H, —(CH2)n-, and —(CH2CH20)n-. Here, n is a natural number of 1 to 100. R3A, R3B, and R3C may all be the same.
Preferably, R4A, R4B, and R4C are each independently similar to R2 or R4 described above. That is, preferably, R4A, R4B, and R4C are each independently selected from the group consisting of H, —OH, methyl, an amine, a terminal alkyne, an alkene, an alkyl acid, an amine acid, sulfonate (SO3−), an aryl group or a derivative thereof, and a heterocyclic compound or a derivative thereof. R4A, R4B, and R4C may all be the same. —R3A-R4A, —R3B-R4B, and —R3C-R4C may each be independently —(CH2)n-H, an oligoethylene glycol chain (—(CH2CH2O)n-H), or (—(CH2CH2O)n-CH3).
Preferably, in general formula (3A) or (3B), R3A, R3B, and R3C are CH2 and R4A, R4B, and R4C are H.
The compound 10 represented by general formula (3B) is one (activated compound 10) obtained by deprotonating the compound 10 represented by general formula (3A).
The compound 10 represented by each of general formulae (3A) and (3B) is also suitable for detection of at least either one of a double-stranded nucleic acid and a quadruplex nucleic acid. The compound 10 represented by each of general formulae (3A) and (3B) has large planarity, and thus, is advantageous for binding to a quadruplex nucleic acid.
The mixture was subjected to heating reflux under an N2 atmosphere for 6 hours, then, the solvent was removed, and the residue was purified with a reverse phase column (SepPak, eluent: acetonitrile-water (0.1% TFA)). The purified matter was freeze-dried, whereby a compound 10 was obtained. The obtained compound 10 was a deep purple solid. The amount of the obtained compound 10 was 8.3 mg, 9.9 μmol, and the yield was 20%. The obtained compound 10 corresponds to the compound in which XA, XB, and XC in formula (2D) are all S.
Analysis data of the obtained compound 10 is as follows.
1H-NMR: 1H-NMR (400 MHZ, DMSO-D6) δ 8.40 (d, J=15 Hz, 2H), 8.30 (s, 2H), 8.24 (d, J=7.6 Hz, 2H), 8.18 (d, J=8.4 Hz, 1H), 8.12 (d, J=8.8 Hz, 2H), 8.02 (d, J=8.0 Hz, 1H), 8.00 (d, J=16 Hz, 2H), 7.86 (d, J=15 Hz, 1H), 7.74 (t, J=8.0 Hz, 2H), 7.68 (t, J=8.2 Hz, 1H), 7.63 (t, J=7.4 Hz, 2H), 7.56 (t, J=7.8 Hz, 1H), 7.51 (d, J=16 Hz, 1H), 4.23 (s, 3H), 4.22 (s, 6H) 13C-NMR: 13C-NMR (101 MHz, DMSO-D6) δ 178.4, 172.2, 170.4, 158.3, 158.0, 149.2, 146.9, 141.7, 141.7, 140.2, 129.0, 128.8, 127.7, 127.3, 126.9, 126.4, 126.2, 123.8, 123.6, 118.4, 118.4, 116.1, 115.6, 115.5, 109.9, 105.6, 35.7, 35.4
ESI-MS: 307.92 (found), 307.57 (calcd. for C36H29N3OS3 2+)
In order to obtain a three-leg type (D3A) like the compound 10 according to the embodiment, it is preferable to use a substance having three aldehyde groups (—CHO) corresponding to the three-leg type, such as 2-hydroxy-1,3,5-benzenetricarbaldehyde described above, as a starting material (a starting material (precursor) corresponding to the donor moiety), for example. When the starting material has two aldehyde groups, a two-leg type (D2A) such as QCy-DT is obtained.
As a production method of the compound 10 other than the production method shown in
In general, when a molecule has an active methylene group (corresponding to the methyl group at position 2 of 2,3-dimethylbenzothiazolium iodide), if the molecule is condensed with an aldehyde through Knoevenagel condensation, an olefin structure (double bond) can be formed. The production method described above uses this. Therefore, as the precursor of the acceptor moieties according to the embodiment, 2-methyl-3-(R1R2)-benzothiazolium iodide (the counter anion is not limited to I−, and may be Cl−, Br−, or a tosyl anion) or 4,5-diphenyl-2-methyl-3-(R1R2)-thiazolium iodide (the counter anion is not limited to I−, and may be Cl−, Br−, or a tosyl anion) may be used. In this case, similar to the production method described above, the structure of the three-leg type (D3A) according to the embodiment can be obtained through Knoevenagel condensation with 2-hydroxy-1,3,5-benzenetricarbaldehyde.
2,3-dimethylbenzothiazolium iodide can be synthesized by causing 2-methylbenzothiazole as a raw material to react with methyl iodide (CH3I). 2-methyl-3-(R1R2)-benzothiazolium iodide (or bromide) can be synthesized by causing 2-methylbenzothiazole as a raw material to react with a compound represented by general formula R2CH2I (or R2CH2Br).
When the compound 10 of the three-leg type (D3A) according to the embodiment is to be produced, the molecules (the precursor for the acceptors) to serve as the source of the acceptors may be of one type, two types, or three types. For example, to a trialdehyde to serve as a donor, a 3 molar equivalent or more of a mixture of two or more types of molecules (the precursor of the acceptors) to serve as the source of the acceptors is added to react, whereby a compound 10 can be generated. In this case, the generated product is a mixture of compounds having different structures.
When a first molecule, a second molecule, and a third molecule to serve as the source of the acceptors are sequentially caused to react with a trialdehyde to serve as the donor, a desired molecule can be bound to a desired position in the compound 10.
In a first experiment, the compound 10 (6 μM) synthesized as shown in “2.3 Production method of compound” and
As described above, with respect to the compound 10, fluorescence changes in accordance with the viscosity of the liquid in which the compound 10 is present. Therefore, when the compound 10 is used, the viscosity of the liquid in which the compound 10 is present can be measured. In the viscosity measurement using the compound 10, at least any one of the fluorescence intensity, the fluorescence wavelength, the fluorescence intensity ratio, and the absorbance which change in accordance with the viscosity is preferably measured as an index for obtaining the viscosity.
With respect to the compound 10, the fluorescence property such as the fluorescence intensity or the excitation wavelength changes in response to rotary motion of the three acceptor moieties. Therefore, when the three acceptor moieties can perform rotary motion, the viscosity measurement is possible. When the rotation speed is controlled according to the difference in the functional group introduced at R1 or R3, the range of viscosity change that can be measured with high accuracy can be controlled. For example, when —(CH2CH20)n- is introduced as R1 or R3, the rotation speed can be controlled by changing the value of n.
In the second experiment, a sample in which 6 μM of nucleic acid was added to 6 μM of the compound 10 synthesized as shown in “2.3 Production method of compound” and
In the second experiment, a fluorescence spectrum (excitation wavelength: 470 nm) of each of the first sample, the second sample, the third sample, and the fourth sample was measured.
As shown in
As shown in
As shown in
As shown in
Thus, when the compound 10 is used as a fluorescent probe (fluorescent dye), a double-stranded nucleic acid can be detected, similar to QCy-DT. The compound 10 can specifically bind to a double-stranded nucleic acid having an AAATTT sequence, similar to QCy-DT. Further, when the compound 10 is used as a fluorescent probe (fluorescent dye), a quadruplex nucleic acid can be detected.
In addition, with respect to the compound 10, the wavelength at which the fluorescence intensity increases when the compound 10 binds to a double-stranded nucleic acid, and the wavelength at which the fluorescence intensity increases when the compound 10 binds to a quadruplex nucleic acid are different from each other. Therefore, based on the difference in the fluorescence wavelength, whether the DNA structure included in the sample is a double-stranded nucleic acid or a quadruplex nucleic acid can be determined.
The compound 10 can also be used in viscosity measurement as described above. Therefore, detection of a nucleic acid and measurement of the viscosity of the environment in which the nucleic acid is present can be simultaneously performed. For example, when the compound 10 has bound to a quadruplex nucleic acid, at least any one of the fluorescence intensity, the fluorescence wavelength, the fluorescence intensity ratio, and the absorbance changes in accordance with the magnitude of the viscosity in the environment in which the quadruplex nucleic acid is present.
Therefore, for example, from the fluorescence spectrum or the like obtained by measurement of a sample containing the compound 10, whether the DNA structure contained in the sample is a double-stranded nucleic acid or a quadruplex nucleic acid can be determined, and the viscosity of the environment in which the nucleic acid is present can be obtained.
<3.3 Third Experiment: Affinity of Interaction of Compound 10 with Quadruplex Nucleic Acid and Double-Stranded Nucleic Acid>
In the third experiment, in order to evaluate the binding affinity between the compound 10 synthesized as shown in “2.3 Production method of compound” and
With respect to the binding affinity between the compound 10 and the quadruplex nucleic acid, as shown in
According to the result shown in
According to the result shown in
Since the compound 10 has a relatively large binding affinity to a nucleic acid, the compound 10 is advantageous as a fluorescent probe for the nucleic acid. It is considered that since the compound 10 has three legs positively charged, the binding force to a nucleic acid negatively charged is large.
In a fourth experiment, quadruplex nucleic acids and double-stranded nucleic acids in fixed cells were stained, using the compound 10 synthesized as shown in “2.3 Production method of compound” and
As shown in
In a fifth experiment, cytotoxicity of the compound 10 synthesized as shown in “2.3 Production method of compound” and
As shown in
In a sixth experiment, quadruplex nucleic acids and double-stranded nucleic acids in viable cells were stained, using the compound 10 synthesized as shown in “2.3 Production method of compound” and
As shown in
In the seventh experiment, it was demonstrated that imaging of the formation process of a quadruplex nucleic acid in a viable cell is possible. In the seventh experiment, pyridostatin (PDS: 20 μM) was added to viable cells stained by the same method as that in the sixth experiment and temporal change of a fluorescence image thereafter was observed. Pyridostatin (PDS) is a reagent for stabilizing quadruplex nucleic acids.
As shown in
As a solvent for the staining liquid (probe solution) having the compound 10, a liquid, such as H20 or 5% glucose, that does not substantially have ions that bind to the compound 10 is preferable. In a case of a solvent (e.g., PBS) having ions that bind to the compound 10, even if the compound 10 is dissolved in the solvent, precipitation occurs with lapse of time. However, in a case of a solvent that does not substantially have ions that bind to the compound 10, precipitation can be prevented. Further, as the solvent, one, such as 5% glucose, whose osmotic pressure is substantially equal to that of a cell is preferable. When the osmotic pressure is substantially equal to that of a cell, the cell can be protected.
In the eighth experiment, the compound 10 (5 μM) was dissolved into each of solvents of H20, 5% glucose, and PBS, and the resultant matter was left to stand at room temperature.
<3.9 Ninth Experiment: Competition Experiment with Hoechist 33258 (Using Fixed HeLa Cells)>
In a ninth experiment, a competition experiment with Hoechist 33258 was performed using fixed HeLa cells. As the staining liquid, one obtained by causing Hoechist 33258 at an arbitrary concentration (0 μM, 1.5 μM, 3.0 μM, 6.0 μM) to coexist in a PBS solution of the compound 10 (6 μM) was used, and the experiment was performed according to an operation similar to that in the fourth experiment.
As shown in
<3.10 Tenth Experiment: Competition Experiment with Hoechist 33258 (Using Living HeLa Cells)>
In a tenth experiment, a competition experiment with Hoechist 33258 was performed using living HeLa cells. As the staining liquid, one obtained by causing Hoechist 33258 at an arbitrary concentration (0 μM, 5.0 μM, 10 μM, 20 μM) to coexist in a 5% glucose solution of the compound 10 (1 μM) was used, and the experiment was performed according to an operation similar to that in the sixth experiment.
As shown in
The present invention is not limited to the above embodiment and examples, and various modifications can be made.
Number | Date | Country | Kind |
---|---|---|---|
2020-206368 | Dec 2020 | JP | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/JP2021/043996 | 11/30/2021 | WO |